Is Franklin Genomic stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
Yes, Franklin Genomic pays dividends. Last time was Friday 7th of January 2022 where the investors holding the stock on Thursday 30th of December 2021 were paid $0.004 per share. Over the last 3 times between 2020 and 2021, Franklin Genomic has paid $0.17 with an average of $0.06 per share.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Franklin Genomic 10 years ago, but if you had invested on Thursday 27th of February 2020 when the price was $23.96, you would have made a profit of $8.19 per share or 34.18%
No, the average daily trading liquidity for Franklin Genomic is $2 132 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Franklin Genomic has N/A of the business financed by loans. This puts the company at N/A risk in periods of high inflation where borrowing costs usually go up. With a N/A cash flow to debt ratio of 0, the company's ability to pay off the debt is N/A. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Franklin Genomic to be low [0 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.09 and is down -0.37 over the last 30 days.